Cancer Research and Treatment

Original Articles

Gastrointestinal cancer

Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells: Boonyakorn Boonsri, Kiren Yacqub-Usman, Pakpoom Thintharua, Kyaw Zwar Myint, Thannicha Sae-Lao, Pam Collier, Chinnawut Suriyonplengsaeng, Noppadol Larbcharoensub, Brinda Balasubramanian, Simran Venkatraman, Isioma U. Egbuniwe, Dhanwant Gomez, Abhik Mukherjee, Supeecha Kumkate, Tavan Janvilisri, Abed M Zaitoun, Thiti Kuakpaetoon, Rutaiwan Tohtong, Anna M Grabowska, David O. Bates, Kanokpan Wongprasert; Cancer Res Treat. 2021;53(2):457-470. Published online October 7, 2020; DOI: https://doi.org/10.4143/crt.2020.585

Abstract PDF Supplementary Material PubReader ePub

Purpose
The potential of members of the epidermal growth factor receptor (ErbB) family as drug targets in cholangiocarcinoma (CCA) has not been extensively addressed. Although phase III clinical trials showed no survival benefits of erlotinib in patients with advanced CCA, the outcome of the standard-of-care chemotherapy treatment for CCA, gemcitabine/cisplatin, is discouraging so we determined the effect of other ErbB receptor inhibitors alone or in conjunction with chemotherapy in CCA cells. Materials and Methods ErbB receptor expression was determined in CCA patient tissues by immunohistochemistry and digital-droplet polymerase chain reaction, and in primary cells and cell lines by immunoblot. Effects on cell viability and cell cycle distribution of combination therapy using ErbB inhibitors with chemotherapeutic drugs was carried out in CCA cell lines. 3D culture of primary CCA cells was then adopted to evaluate the drug effect in a setting that more closely resembles in vivo cell environments.
Results
CCA tumors showed higher expression of all ErbB receptors compared with resection margins. Primary and CCA cell lines had variable expression of erbB receptors. CCA cell lines showed decreased cell viability when treated with chemotherapeutic drugs (gemcitabine and 5-fluorouracil) but also with ErbB inhibitors, particularly afatinib, and with a combination. Sequential treatment of gemcitabine with afatinib was particularly effective. Co-culture of CCA primary cells with cancer-associated fibroblasts decreased sensitivity to chemotherapies, but sensitized to afatinib. Conclusion Afatinib is a potential epidermal growth factor receptor targeted drug for CCA treatment and sequential treatment schedule of gemcitabine and afatinib could be explored in CCA patients.

Citations

Citations to this article as recorded by

Rational synthesis and evaluation of 2,4-diamino-thieno[2,3-d]pyrimidines as antitumor agents
Yumeng Gao, Ainv Zhang, Li Li, Fengxu Wu, Yanggen Hu
Journal of Saudi Chemical Society.2024; 28(1): 101794. CrossRef
Identification and validation of a novel ferroptosis-related gene signature for prognosis and potential therapeutic target prediction in cholangiocarcinoma
Apiwit Sae-fung, Apiwat Mutirangura, Siriporn Jitkaew
Frontiers in Immunology.2023;[Epub] CrossRef
Preclinical evidence for anaplastic lymphoma kinase inhibitors as novel therapeutic treatments for cholangiocarcinoma
Kyaw Zwar Myint, Mireia Sueca-Comes, Pamela Collier, Brinda Balasubramanian, Simran Venkatraman, John Gordan, Abed M. Zaitoun, Abhik Mukherjee, Arvind Arora, Noppadol Larbcharoensub, Chinnawut Suriyonplengsaeng, Kanokpan Wongprasert, Tavan Janvilisri, Dha
Frontiers in Oncology.2023;[Epub] CrossRef
CP-673451, a Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor, Induces Apoptosis in Opisthorchis viverrini-Associated Cholangiocarcinoma via Nrf2 Suppression and Enhanced ROS
Jinchutha Duangdara, Boonyakorn Boonsri, Apinya Sayinta, Kittiya Supradit, Pakpoom Thintharua, Supeecha Kumkate, Chinnawut Suriyonplengsaeng, Noppadol Larbcharoensub, Somkit Mingphruedhi, Narongsak Rungsakulkij, Paramin Muangkaew, Pongsatorn Tangtawee, Wa
Pharmaceuticals.2023; 17(1): 9. CrossRef
Lactic acidosis promotes aggressive features of cholangiocarcinoma cells via upregulating ALDH1A3 expression through EGFR axis
Ubonrat Thamrongwaranggoon, Marutpong Detarya, Wunchana Seubwai, Charupong Saengboonmee, Shinjiro Hino, Tomoaki Koga, Mitsuyoshi Nakao, Sopit Wongkham
Life Sciences.2022; 302: 120648. CrossRef
Advances of cancer-associated fibroblasts in liver cancer
Hao Peng, Erwei Zhu, Yewei Zhang
Biomarker Research.2022;[Epub] CrossRef
RTK25: A Comprehensive Molecular Profiling Strategy in Cholangiocarcinoma Using an Integrated Bioinformatics Approach
Brinda Balasubramanian, Simran Venkatraman, Tavan Janvilisri, Tuangporn Suthiphongchai, Siriporn Jitkaew, Jittiyawadee Sripa, Rutaiwan Tohtong
Pharmaceuticals.2021; 14(9): 898. CrossRef

10,261 View
397 Download
7 Crossref

CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy: Dae-Won Lee, Seock-Ah Im, Yu Jung Kim, Yaewon Yang, Jiyoung Rhee, Im Il Na, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, In Sil Choi, Do-Youn Oh, Jee Hyun Kim, Tae-You Kim, Yung-Jue Bang; Cancer Res Treat. 2017;49(3):807-815. Published online January 18, 2017; DOI: https://doi.org/10.4143/crt.2016.326

Abstract PDF PubReader ePub

Purpose
While tumor markers (carbohydrate antigen 19-9 [CA 19-9] and carcinoembryonic antigen [CEA]) can aid in the diagnosis of biliary tract cancer, their prognostic role has not been clearly elucidated. Therefore, this study was conducted to evaluate the prognostic role of tumor markers and tumor marker change in patients with advanced biliary tract cancer.
Materials and Methods
Patients with pathologically proven metastatic or relapsed biliary tract cancer who were treated in a phase II trial of first-line S-1 and cisplatin chemotherapy were enrolled. Serum tumor markers were measured at baseline and after the first cycle of chemotherapy.
Results
Among a total of 104 patients, 80 (77%) had elevated baseline tumor markers (69 with CA 19-9 elevation and 40 with CEA). A decline ≥ 30% of the elevated tumor marker level after the first cycle of chemotherapy conferred an improved time to progression (TTP), overall survival (OS), and better chemotherapy response. Multivariate analysis revealed tumor marker decline as an independent positive prognostic factor of TTP (adjusted hazard ratio [HR], 0.44; p=0.003) and OS (adjusted HR, 0.37; p < 0.001). Subgroup analysis revealed similar results in each group of patients with CA 19-9 elevation and CEA elevation. In addition, elevated baseline CEA was associated with poor survival in both univariate and multivariate analysis.
Conclusion
Tumor marker decline was associated with improved survival in biliary tract cancer. Measuring tumor marker after the first cycle of chemotherapy can be used as an early assessment of treatment outcome.

Citations

Citations to this article as recorded by

Clinical epidemiology of gallbladder cancer in North-Central India and association of immunological markers, NLR, MLR and PLR in the diagnostic/prognostic prediction of GBC
Jyotsna Singh, Durgesh Shukla, Sanjiv Gupta, Braj Raj Shrivastav, Pramod Kumar Tiwari
Cancer Treatment and Research Communications.2021; 28: 100431. CrossRef
Neoadjuvant Intraperitoneal Chemotherapy in Patients with Pseudomyxoma Peritonei—A Novel Treatment Approach
Aruna Prabhu, Andreas Brandl, Satoshi Wakama, Shouzou Sako, Haruaki Ishibashi, Akiyoshi Mizumoto, Nobuyuki Takao, Kousuke Noguchi, Shunsuke Motoi, Masumi Ichinose, Yang Liu, Yutaka Yonemura
Cancers.2020; 12(8): 2212. CrossRef
Clinical and Translational Research Challenges in Biliary Tract Cancers
Angela Lamarca, Melissa Frizziero, Mairéad G. McNamara, Juan W. Valle
Current Medicinal Chemistry.2020; 27(29): 4756. CrossRef
Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin
Min su You, Ji Kon Ryu, Young Hoon Choi, Jin Ho Choi, Gunn Huh, Woo Hyun Paik, Sang Hyub Lee, Yong-Tae Kim
BMC Cancer.2019;[Epub] CrossRef
Efficacy of interventional therapy and effect on inflammatory factors in patients with gastric cancer after chemotherapy
Puzhao Wu, Jing Wang
Oncology Letters.2019;[Epub] CrossRef
CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer
Naminatsu Takahara, Yousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, Kei Saito, Kensaku Noguchi, Tatsunori Suzuki, Tomoka Nakamura, Tatsuya Sato, Kazunaga Ishigaki, Ryunosuke Hakuta, Tsuyoshi Takeda, Rie Uchino, Suguru Mizuno, Hirofumi Kogure, Minoru Tada
Cancer Chemotherapy and Pharmacology.2017; 80(6): 1105. CrossRef

12,841 View
203 Download
7 Web of Science
6 Crossref

Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen: Changhoon Yoo, Bum Jun Kim, Kyu-pyo Kim, Jae-Lyun Lee, Tae Won Kim, Baek-Yeol Ryoo, Heung-Moon Chang; Cancer Res Treat. 2017;49(3):759-765. Published online November 9, 2016; DOI: https://doi.org/10.4143/crt.2016.371

Abstract PDF Supplementary Material PubReader ePub

Purpose
Pancreatic acinar cell carcinoma (ACC) is a rare cancer of the exocrine pancreas. Because of its rare incidence, the efficacy of chemotherapy in this patient population has been largely unknown. Therefore, we retrospectively analyzed the outcomes of patients with advanced pancreatic ACC who received chemotherapy.
Materials and Methods
Between January 1997 and March 2015, 15 patients with unresectable or metastatic pancreatic ACC who received systemic chemotherapy were identified in Asan Medical Center, Korea.
Results
The median age was 58 years. Eleven and four patients had recurrent/metastatic and locally advanced unresectable disease. The median overall survival in all patients was 20.9 months (95% confidence interval [CI], 15.7 to 26.1). As first-line therapy, intravenous 5-fluorouracil were administered in four patients (27%), gemcitabine in five (33%), gemcitabine plus capecitabine in two (13%), oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) in two (13%), and concurrent chemoradiotherapy followed by capecitabine maintenance therapy in two (13%). The objective response rate (ORR) to chemotherapy alone was 23% and the median progression-free survival (PFS) was 5.6 months (95% CI, 2.8 to 8.4). After progression, second- line chemotherapy was administered in eight patients, while four patients received FOLFOX and the other four patients received gemcitabine. The ORR was 38%, and patients administered FOLFOX had significantly better PFS than those administered gemcitabine (median, 6.5 months vs. 1.4 months; p=0.007). The ratio of time to tumor progression (TTP) during first-line chemotherapy to TTP at second-line chemotherapy was significantly higher in patients administered FOLFOX (4.07; range, 0.87 to 8.30) than in those administered gemcitabine (0.12; range, 0.08 to 0.25; p=0.029).
Conclusion
Our results suggest that oxaliplatin-containing regimens may have improved activity against pancreatic ACC.

Citations

Citations to this article as recorded by

Clinical Outcomes and Molecular Profiling of Pancreatic Acinar Cell Carcinoma: A Retrospective Study
Cody Eslinger, Bobak Seddighzadeh, Claire Yee, Zaid Elsabbagh, Rish Pai, Chris Hartley, Jason Starr, Tanios Bekaii-Saab, Thorvardur R. Halfdanarson, Mohamad Bassam Sonbol
JCO Precision Oncology.2025;[Epub] CrossRef
Pediatric pancreatic acinar cell carcinoma with a non-canonical BRAF-KMT2C fusion and a classic SND1-BRAF fusion: a case report and literature review
Yaqin Wang, Jiasi Zhang, Dimin Nie, Ai Zhang, Qun Hu, Aiguo Liu
BMC Pediatrics.2025;[Epub] CrossRef
Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment
Kenji Ikezawa, Makiko Urabe, Yugo Kai, Ryoji Takada, Hirofumi Akita, Shigenori Nagata, Kazuyoshi Ohkawa
Japanese Journal of Clinical Oncology.2024; 54(3): 271. CrossRef
Pathological complete response with FOLFIRINOX therapy for recurrence of pancreatic acinar cell carcinoma
Katsuhito Teramatsu, Nao Fujimori, Masatoshi Murakami, Sho Yasumori, Kazuhide Matsumoto, Kohei Nakata, Masafumi Nakamura, Yutaka Koga, Yoshinao Oda, Yoshihiro Ogawa
Clinical Journal of Gastroenterology.2024; 17(4): 776. CrossRef
Complete pathological response to pembrolizumab in pretreated pancreatic acinar cell carcinoma
Valeria Merz, Francesca Maines, Stefano Marcucci, Chiara Sartori, Michela Frisinghelli, Chiara Trentin, Dzenete Kadrija, Francesco Giuseppe Carbone, Andrea Michielan, Armando Gabbrielli, Davide Melisi, Mattia Barbareschi, Alberto Brolese, Orazio Caffo
Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef
A narrative review on rare types of pancreatic cancer: should they be treated as pancreatic ductal adenocarcinomas?
Victor Hugo Fonseca de Jesus, Mauro Daniel Spina Donadio, Ângelo Borsarelli Carvalho de Brito, Arthur Conelian Gentilli
Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef
Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma
Alex B. Blair, Shannon N. Radomski, Joanne Chou, Mengyuan Liu, Thomas Clark Howell, Wungki Park, Eileen M. O’Reilly, Lei Zheng, Vinod P. Balachandran, Alice C. Wei, T. Peter Kingham, Michael I. D’Angelica, Jeffrey Drebin, Sabino Zani, Dan G. Blazer, Richa
Annals of Surgical Oncology.2024;[Epub] CrossRef
A case of unresectable ectopic acinar cell carcinoma developed in the portal vein in complete response to FOLFIRINOX therapy
Shinnosuke Nakayama, Akihisa Fukuda, Tadayuki Kou, Manabu Muto, Hiroshi Seno
Clinical Journal of Gastroenterology.2023; 16(4): 610. CrossRef
New treatment insights into pancreatic acinar cell carcinoma: case report and literature review
Fangrui Zhao, Dashuai Yang, Tangpeng Xu, Jiahui He, Jin Guo, Xiangpan Li
Frontiers in Oncology.2023;[Epub] CrossRef
A resected case of acinar cell carcinoma of the pancreas with liver metastasis following chemotherapy using modified FOLFIRINOX
Shuhei Yamada, Haruka Motegi, Yoshiki Kurihara, Tomonori Shimbo, Isao Kikuchi, Toshiki Wakabayashi, Tsutomu Sato
Surgical Case Reports.2023;[Epub] CrossRef
A Simple Overview of Pancreatic Cancer Treatment for Clinical Oncologists
Ingrid Garajová, Marianna Peroni, Fabio Gelsomino, Francesco Leonardi
Current Oncology.2023; 30(11): 9587. CrossRef
Progressive nodule-like lesions on bilateral lower limbs
FA Yang, KS Cheng, JW Chou
Journal of Postgraduate Medicine.2023; 69(1): 50. CrossRef
Mixed pancreatic acinar cell-ductal adenocarcinoma: Complexities in diagnosis and treatment
Abdullah Nasser, Catherine L. Forse, Cynthia Walsh, Terence Moyana, Rakesh Goel
Current Problems in Cancer: Case Reports.2022; 5: 100144. CrossRef
Optimizing Chemotherapy of Pancreatic Acinar Cell Carcinoma: Our Experiences and Pooled Analysis of Literature
Jian-Ying Xu, Wen-Long Guan, Shi-Xun Lu, Xiao-Li Wei, Wen-Jie Shi, Chao Ren, Yu-Hong Li, Sheng-Ping Li, Miao-Zhen Qiu, Feng-Hua Wang
Clinical Medicine Insights: Oncology.2022;[Epub] CrossRef
Successful conversion surgery after FOLFIRINOX therapy in a patient with advanced pancreatic acinar cell carcinoma with a solitary peritoneal dissemination: A case report
Sunao Uemura, Hiromichi Maeda, Nobuhisa Tanioka, Sachi Yamaguchi, Masaya Munekage, Hiroyuki Kitagawa, Tsutomu Namikawa, Shota Yamamoto, Takuhiro Kohsaki, Mitsuko Iguchi, Kazushige Uchida, Kazuhiro Hanazaki
Cancer Reports.2022;[Epub] CrossRef
Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma associated with a germline BRCA 2 mutation, revealed by severe panniculitis
Margaux Lelong, Jean‐Luc Raoul, Yann Touchefeu, Jean‐Marie Berthelot, Paul Arnolfo, Tamara Matysiak‐Budnik, Hélène Senellart
Clinical Case Reports.2022;[Epub] CrossRef
Multicenter Retrospective Analysis of Chemotherapy for Advanced Pancreatic Acinar Cell Carcinoma
Hideaki Takahashi, Masafumi Ikeda, Satoshi Shiba, Hiroshi Imaoka, Akiko Todaka, Kazuhiko Shioji, Kei Yane, Yasushi Kojima, Satoshi Kobayashi, Akinori Asagi, Masato Ozaka, Ryoji Takada, Yoshikuni Nagashio, Shigeru Horiguchi, Akiyoshi Kasuga, Eiichiro Suzuk
Pancreas.2021; 50(1): 77. CrossRef
Efficacy of chemotherapy combined with toripalimab in PD-L1–positive and high tumor mutation burden pancreatic acinar cell carcinoma: case report
Huanji Xu, Xin Wang, Sheng Zhou, Qiancheng Hu, Dan Cao
Tumori Journal.2021; 107(6): NP24. CrossRef
Metastatic Acinar Cell Carcinoma of the Pancreas
Elena Busch, Wiebke Werft, Nina Bougatf, Thilo Hackert, Dirk Jäger, Christoph Springfeld, Anne Katrin Berger
Pancreas.2021; 50(3): 300. CrossRef
Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes
Vishwajith Sridharan, Mari Mino-Kenudson, James M. Cleary, Osama E. Rahma, Kimberly Perez, Jeffrey W. Clark, Thomas E. Clancy, Douglas A. Rubinson, Lipika Goyal, Fateh Bazerbachi, Kavel H. Visrodia, Motaz Qadan, Aparna Parikh, Cristina R. Ferrone, Brenna
Pancreatology.2021; 21(6): 1119. CrossRef
Down‐regulation of metabolic pathways could offset the poor prognosis conferred by co‐existent diabetes mellitus in pancreatic (head) adenocarcinoma
Nilesh Gardi, Madhura Ketkar, Ross A. McKinnon, Stephen J. Pandol, Shilpee Dutt, Savio G. Barreto
ANZ Journal of Surgery.2021; 91(11): 2466. CrossRef
Pathological complete response in a patient with metastatic pancreatic acinar cell carcinoma who received a chemotherapy regimen containing cisplatin and irinotecan
Hiromitsu Maehira, Hiroya Iida, Haruki Mori, Nobuhito Nitta, Aya Tokuda, Katsushi Takebayashi, Sachiko Kaida, Toru Miyake, Akiko Matsubara, Masaji Tani
Clinical Journal of Gastroenterology.2021; 14(6): 1772. CrossRef
Survival Outcome and Prognostic Factors for Pancreatic Acinar Cell Carcinoma: Retrospective Analysis from the German Cancer Registry Group
Ekaterina Petrova, Joachim Wellner, Anne K. Nording, Rüdiger Braun, Kim C. Honselmann, Louisa Bolm, Richard Hummel, Monika Klinkhammer-Schalke, Sylke Ruth Zeissig, Kees Kleihues van Tol, Sylvia Timme-Bronsert, Peter Bronsert, Sergey Zemskov, Tobias Keck,
Cancers.2021; 13(23): 6121. CrossRef
The Unusual Suspects of the Pancreas—Understanding Pancreatic Acinar Cell Carcinomas and Adenomas
Andreas Minh Luu, Tim Fahlbusch, Johanna Munding, Waldemar Uhl, Chris Braumann
Journal of Gastrointestinal Cancer.2020; 51(1): 172. CrossRef
Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report
Mariacristina Di Marco, Riccardo Carloni, Stefania De Lorenzo, Elisa Grassi, Andrea Palloni, Francesca Formica, Stefano Brocchi, Daria Maria Filippini, Rita Golfieri, Giovanni Brandi
World Journal of Clinical Cases.2020; 8(7): 1241. CrossRef
Robot-assisted combined pancreatectomy/hepatectomy for metastatic pancreatic acinar cell carcinoma: case report and review of the literature
Anthony Michael Villano, Dany Barrak, Anish Jain, Erin Meslar, Pejman Radkani, Walid Chalhoub, Nadim Haddad, Emily Winslow, Thomas Fishbein, Jason Hawksworth
Clinical Journal of Gastroenterology.2020; 13(5): 973. CrossRef
Patients With Acinar Cell Carcinoma of the Pancreas After 2005
Yuan Zong, Changsong Qi, Zhi Peng, Lin Shen, Jun Zhou
Pancreas.2020; 49(6): 781. CrossRef
One size does not fit all for pancreatic cancers: A review on rare histologies and therapeutic approaches
Monica Niger, Michele Prisciandaro, Maria Antista, Melissa Anna Teresa Monica, Laura Cattaneo, Natalie Prinzi, Sara Manglaviti, Federico Nichetti, Marta Brambilla, Martina Torchio, Francesca Corti, Sara Pusceddu, Jorgelina Coppa, Vincenzo Mazzaferro, Fili
World Journal of Gastrointestinal Oncology.2020; 12(8): 833. CrossRef
Successful BRAF/MEK inhibition in a patient with BRAFV600E-mutated extrapancreatic acinar cell carcinoma
Elena Busch, Simon Kreutzfeldt, Abbas Agaimy, Gunhild Mechtersheimer, Peter Horak, Benedikt Brors, Barbara Hutter, Martina Fröhlich, Sebastian Uhrig, Philipp Mayer, Evelin Schröck, Albrecht Stenzinger, Hanno Glimm, Dirk Jäger, Christoph Springfeld, Stefan
Molecular Case Studies.2020; 6(4): a005553. CrossRef
Pancreatic panniculitis and elevated serum lipase in metastasized acinar cell carcinoma of the pancreas: A case report and review of literature
Rainer Christoph Miksch, Tobias S Schiergens, Maximilian Weniger, Matthias Ilmer, Philipp M Kazmierczak, Markus O Guba, Martin K Angele, Jens Werner, Jan G D'Haese
World Journal of Clinical Cases.2020; 8(21): 5304. CrossRef
The contemporary trend in worsening prognosis of pancreatic acinar cell carcinoma: A population-based study
Nie Duorui, Bin Shi, Tao Zhang, Chuyao Chen, Chongkai Fang, Zhijun Yue, Peng Wu, Zhiming Wu, Xuewu Huang, Meng Li, Girijesh Kumar Patel
PLOS ONE.2020; 15(12): e0243164. CrossRef
Pancreatic acinar cell carcinoma diagnosed by BCL10 staining: A case report
Kei YAMANE, Takayuki ANAZAWA, Toshihiko MASUI, Kazuyuki NAGAI, Seiichiro TADA, Kenta INOGUCHI, Kenzo NAKANO, Yuichiro UCHIDA, Akitada YOGO, Kyouichi TAKAORI, Shinji UEMOTO
Suizo.2019; 34(1): 46. CrossRef
Prognostic Factors of Acinar Cell Carcinomas
Axel Egal, Jérôme Cros, Magali Svrcek, Laurence Chiche, Geneviève Belleannee, Flora Poizat, Lionel Jouffret, Frédérique Maire, Louis de Mestier, Pascal Hammel
Pancreas.2019; 48(10): 1393. CrossRef
EGFR amplification induces sensitivity to antiEGFR therapy in pancreatic acinar cell carcinoma
Corentin Richard, Julie Niogret, Romain Boidot, Francois Ghiringhelli
World Journal of Gastrointestinal Oncology.2018; 10(4): 103. CrossRef
Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors
Oronzo Brunetti, Giuseppe Aprile, Paolo Marchetti, Enrico Vasile, Andrea Casadei Gardini, Mario Scartozzi, Sandro Barni, Sara Delfanti, Fernando De Vita, Francesco Di Costanzo, Michele Milella, Chiara Alessandra Cella, Rossana Berardi, Ivana Cataldo, Aldo
Pancreas.2018; 47(6): 759. CrossRef
Pancreatic acinar cell carcinoma—case report and literature review
Zhang Xing-mao, Zhang Hong-juan, Li Qing, He Qiang
BMC Cancer.2018;[Epub] CrossRef
Successful chemotherapy with modified FOLFIRINOX for pancreatic acinar cell carcinoma
Minami Hashimoto, Takuto Hikichi, Tomohiro Suzuki, Mayumi Tai, Osamu Ichii, Nobuo Matsuhashi, Eisaku Kita, Shintaro Takahashi, Yoshinori Okubo, Hando Hakozaki, Yutaka Ejiri, Hiromasa Ohira
Clinical Journal of Gastroenterology.2017; 10(6): 564. CrossRef

11,102 View
372 Download
38 Web of Science
37 Crossref

A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine: Keun-Wook Lee, Bum Jun Kim, Mi-Jung Kim, Hye Sook Han, Jin Won Kim, Young Iee Park, Sook Ryun Park; Cancer Res Treat. 2017;49(3):706-716. Published online October 18, 2016; DOI: https://doi.org/10.4143/crt.2016.216

Abstract PDF PubReader ePub

Purpose
This study evaluated the re-challenge of S-1 or cisplatin in combination with docetaxel in metastatic gastric cancer (MGC) that had progressed on a cisplatin plus either S-1 or capecitabine regimen.
Materials and Methods
Patients with progressive disease after first-line cisplatin plus S-1 or capecitabine were randomized to receive 3-week cycles of docetaxel 75 mg/m² intravenously (IV) on D1 (D), docetaxel 60 mg/m² IV plus cisplatin 60 mg/m² IV on D1 (DC), or docetaxel 60 mg/m² IV D1 plus oral S-1 30 mg/m² twice a day on D1-14 (DS).
Results
Seventy-two patients were randomized to the D (n=23), DC (n=24), or DS (n=25) group. The confirmed response rate was 4.3% (95% confidence interval [CI], 0% to 12.6%), 4.3% (95% CI, 0% to 12.6%), and 8.7% (95% CI, 0% to 20.2%) for the D, DC, and DS groups, respectively. Compared to the D arm, the DS arm had a better progression-free survival (2.7 months vs. 1.3 months, p=0.034) without any deterioration in safety or quality of life, whereas the DC arm had a similar progression-free survival (1.8 months vs. 1.3 months, p=0.804) and poorer overall survival (5.6 months vs. 10.0 months, p=0.035).
Conclusion
A re-challenge with S-1, but not cisplatin, in combination with docetaxel has potential anticancer benefits over docetaxel alone in MGC with progression after prior cisplatin plus S-1 or capecitabine.

Citations

Citations to this article as recorded by

Network Meta-analysis of Randomized Controlled Trials in Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: Comparisons Involving Ramucirumab
Yulia D’yachkova, Astra M. Liepa, Rajat Goel, Veronika Earley-Valovic, Abby Paine, Palvi Gupta, Kaisa Taipale
Journal of Gastrointestinal Cancer.2025;[Epub] CrossRef
Efficacy and safety of docetaxel plus S-1-based therapy in gastric cancer: a quantitative evidence synthesis of randomized controlled trials
Hui-Fen Lv, Li-Feng Qin, Rui-Zhi Ran, Xue-Ping Jiang, Fang-Yu Zhao, Bo Li
Frontiers in Pharmacology.2024;[Epub] CrossRef
Clinical Outcomes for Previously Treated Patients with Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Literature Review and Meta-Analysis
Lauren A. Abderhalden, Ping Wu, Mayur M. Amonkar, Brian M. Lang, Sukrut Shah, Fan Jin, Andrew M. Frederickson, Ali Mojebi
Journal of Gastrointestinal Cancer.2023; 54(4): 1031. CrossRef
Platinum-Based Chemotherapy ‘Rechallenge’ in Advanced Non-ovarian Solid Malignancies
J. Hack, S.J. Crabb
Clinical Oncology.2022; 34(8): e329. CrossRef
Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences
Alison Rowsell, Samantha C. Sodergren, Vassilios Vassiliou, Anne-Sophie Darlington, Marianne G. Guren, Bilal Alkhaffaf, Chantelle Moorbey, Kristopher Dennis, Mitsumi Terada
Gastric Cancer.2022; 25(4): 665. CrossRef
Considerations on the mechanics and sample sizes for early trials of targeted agents and immunotherapy in oncology
Elisabeth Coart, Everardo D. Saad
Expert Review of Precision Medicine and Drug Development.2021; 6(4): 271. CrossRef
Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Daniel V. Catenacci, Joseph Chao, Kei Muro, Salah Eddin Al-Batran, Samuel J. Klempner, Zev A. Wainberg, Manish A. Shah, Sun Young Rha, Atsushi Ohtsu, Astra M. Liepa, Holly Knoderer, Anindya Chatterjee, Eric Van Cutsem
The Oncologist.2021; 26(10): e1704. CrossRef
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma
Yoko Tomita, Max Moldovan, Rachael Chang Lee, Amy HC Hsieh, Amanda Townsend, Timothy Price
Cochrane Database of Systematic Reviews.2020;[Epub] CrossRef
Results of the use of ramucirumab in combination with irinotecan and fluoropyrimidines in the second-line chemotherapy for disseminated gastric cancer
N. S. Besova, T. A. Titova, D. L. Stroyakovsky, E. V. Perminova, S. G. Bagrova, E. S. Obarevich, V. A. Gorbunova, E. V. Artamonova, I. S. Stilidi
Medical Council.2019; (10): 100. CrossRef
Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis
Bo Li, Lian Chen, Hong-Liang Luo, Feng-Ming Yi, Yi-Ping Wei, Wen-Xiong Zhang
World Journal of Clinical Cases.2019; 7(5): 600. CrossRef
A Bayesian Network Meta-Analysis for Identifying the Optimal Taxane-Based Chemotherapy Regimens for Treating Gastric Cancer
Dan Zhang, Jia-Rui Wu, Xiao-Jiao Duan, Kai-Huan Wang, Yi Zhao, Meng-Wei Ni, Shu-Yu Liu, Xiao-Meng Zhang, Bing Zhang
Frontiers in Pharmacology.2019;[Epub] CrossRef
Systemic therapy for previously treated advanced gastric cancer: A systematic review and network meta-analysis
Ji Cheng, Ming Cai, Xiaoming Shuai, Jinbo Gao, Guobin Wang, Kaixiong Tao
Critical Reviews in Oncology/Hematology.2019; 143: 27. CrossRef
Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis
Jessy Joy van Kleef, Emil ter Veer, Héctor G van den Boorn, Sandor Schokker, Lok Lam Ngai, Mariska J Prins, Nadia Haj Mohammad, Lonneke V van de Poll-Franse, Aeilko H Zwinderman, Martijn G H van Oijen, Mirjam A G Sprangers, Hanneke W M van Laarhoven
JNCI: Journal of the National Cancer Institute.2019;[Epub] CrossRef

10,941 View
358 Download
13 Web of Science
13 Crossref

Proton Pump Inhibition Enhances the Cytotoxicity of Paclitaxel in Cervical Cancer: Taejong Song, Hye-Kyung Jeon, Ji Eun Hong, Jung-Joo Choi, Tae-Joong Kim, Chel Hun Choi, Duk-Soo Bae, Byoung-Gie Kim, Jeong-Won Lee; Cancer Res Treat. 2017;49(3):595-606. Published online September 27, 2016; DOI: https://doi.org/10.4143/crt.2016.034

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study was conducted to investigate whether a proton pump inhibitor (PPI) could enhance chemosensitivity via the inhibition of vacuolar-type H+ ATPase (V-ATPase) in cervical cancer.
Materials and Methods
The expression of V-ATPase was evaluated in 351 formalin-fixed, paraffin-embedded human cervical cancer tissues using immunohistochemistry and compared with clinicopathologic risk factors for disease prognosis. The influence of cell proliferation and apoptosis following V-ATPase siRNA transfection or esomeprazole pretreatment was assessed in cervical cancer cell lines using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and enzyme-linked immunosorbent assay, respectively.
Results
Immunohistochemical analysis revealed that V-ATPase was expressed in about 60% of cervical cancer tissue samples (211/351), and the expression was predominantly found in adenocarcinoma histology (p=0.016). Among patients with initially bulky cervical cancer (n=89), those with V-ATPase expression had shorter disease-free survival (p=0.005) and overall survival (p=0.023). Co-treatment with V-ATPase siRNA or esomeprazole with paclitaxel significantly decreased the cell proliferation of cervical cancer cell lines, including HeLa and INT407, compared to cell lines treated with paclitaxel alone (p < 0.01). Moreover, V-ATPase siRNA or esomeprazole followed by paclitaxel significantly increased the expression of active caspase-3 in these cells compared to cells treated with paclitaxel alone (both, p < 0.05).
Conclusion
V-ATPase was predominantly expressed in cervical adenocarcinoma, and the expression of V-ATPases was associated with poor prognosis. The inhibition of V-ATPase via siRNA or PPI (esomeprazole) might enhance the chemosensitivity of paclitaxel in cervical cancer cells.

Citations

Citations to this article as recorded by

Proton Pump Inhibitor Use and Obesity-Associated Cancer in the Women’s Health Initiative
Tarah J. Ballinger, Zora Djuric, Sagar Sardesai, Kathleen M. Hovey, Chris A. Andrews, Theodore M. Brasky, Jian Ting Zhang, Thomas E Rohan, Nazmus Saquib, Aladdin H. Shadyab, Michael Simon, Jean Wactawski-Wende, Robert Wallace, Ikuko Kato
Nutrition and Cancer.2023; 75(1): 265. CrossRef
Esomeprazole Alleviates Cisplatin Resistance by Inhibiting the AKT/mTOR Pathway in Ovarian Cancer Cells
Jingya Duan, Zisen Zhang, Jinfeng Du, Jihua Zhang, Minmin Li, Canyu Li
OncoTargets and Therapy.2023; Volume 16: 425. CrossRef
Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota
Liang Tian, Chongfei Huang, Wenkang Fu, Long Gao, Ningning Mi, Mingzhen Bai, Haidong Ma, Chao Zhang, Yawen Lu, Jinyu Zhao, Xianzhuo Zhang, Ningzu Jiang, Yanyan Lin, Ping Yue, Jinqiu Yuan, Wenbo Meng
Frontiers in Pharmacology.2023;[Epub] CrossRef
Depression Events Associated with Proton-Pump Inhibitors in Postmarketing Drug Surveillance Data
Tigran Makunts, Haroutyun Joulfayan, Kenneth Ta, Ruben Abagyan
Pharmacoepidemiology.2023; 2(3): 272. CrossRef
Association between Proton Pump Inhibitor Use and the Risk of Female Cancers: A Nested Case-Control Study of 23 Million Individuals
Nhi Thi Hong Nguyen, Chih-Wei Huang, Ching-Huan Wang, Ming-Chin Lin, Jason C. Hsu, Min-Huei Hsu, Usman Iqbal, Phung-Anh Nguyen, Hsuan-Chia Yang
Cancers.2022; 14(24): 6083. CrossRef
Emerging insights on the role of V‐ATPase in human diseases: Therapeutic challenges and opportunities
Cátia Santos‐Pereira, Lígia R. Rodrigues, Manuela Côrte‐Real
Medicinal Research Reviews.2021; 41(4): 1927. CrossRef
Omeprazole improves chemosensitivity of gastric cancer cells by m6A demethylase FTO-mediated activation of mTORC1 and DDIT3 up-regulation
Shuitu Feng, Guoqin Qiu, Lihong Yang, Lihua Feng, Xin Fan, Fang Ren, Kaida Huang, Yide Chen
Bioscience Reports.2021;[Epub] CrossRef
Precise Cancer Anti-acid Therapy Monitoring Using pH-Sensitive MnO2@BSA Nanoparticles by Magnetic Resonance Imaging
Rong A, Yuzhu Yao, Xiaolu Guo, Weiqi Jiang, Meng Jiang, Jie Yang, Yingbo Li, Olagbaju Oluwatosin Atinuke, Xuesong Hu, Yuanyuan Li, Xiance Wang, Lili Yang, Xiangliang Yang, Kai Wang, Jun Hu, Xilin Sun
ACS Applied Materials & Interfaces.2021; 13(16): 18604. CrossRef
Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition
Deepak Babu, Anwita Mudiraj, Neera Yadav, Chandrashekhar Y.B.V.K., Manas Panigrahi, Phanithi Prakash Babu
Cellular Oncology.2021; 44(4): 889. CrossRef
How can proton pump inhibitors damage central and peripheral nervous systems?
Tigran Makunts, Ruben Abagyan
Neural Regeneration Research.2020; 15(11): 2041. CrossRef
Exploring the Therapeutic Potential of Membrane Transport Proteins: Focus on Cancer and Chemoresistance
Shekoufeh Almasi, Yassine El Hiani
Cancers.2020; 12(6): 1624. CrossRef
Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells
Valentina Ranzuglia, Ilaria Lorenzon, Ilenia Pellarin, Maura Sonego, Alessandra Dall’Acqua, Sara D’Andrea, Sara Lovisa, Ilenia Segatto, Michela Coan, Jerry Polesel, Diego Serraino, Patrizia Sabatelli, Paola Spessotto, Barbara Belletti, Gustavo Baldassarre
Oncogene.2020; 39(40): 6370. CrossRef
Elevated expression of the V‐ATPase D2 subunit triggers increased energy metabolite levels in KrasG12D‐driven cancer cells
Jigang Yang, Feihu Guo, Leilei Yuan, Guangxin Lv, Jianhua Gong, Jing Chen
Journal of Cellular Biochemistry.2019; 120(7): 11690. CrossRef
Pantoprazole attenuates tumorigenesis via inhibition of exosomal secretion in a rat model of hepatic precancerous lesion induced by diethylnitrosamine and 2‐acetamidofluorene
Marwa Matboli, Asmaa Abd ElGwad, Amany H. Hasanin, Ahmed El‐Tawdi, Eman K. Habib, Rasha Ahmed` Elmansy, Doaa Ibrahim, Hanan Shehata, Fathy Tash
Journal of Cellular Biochemistry.2019; 120(9): 14946. CrossRef
Vacuolar ATPase as a potential therapeutic target and mediator of treatment resistance in cancer
Bradleigh Whitton, Haruko Okamoto, Graham Packham, Simon J. Crabb
Cancer Medicine.2018; 7(8): 3800. CrossRef
Protein Pump Inhibitors Esomeprazole and Pantoprazole Increase the Chemosensitivity of CML cells against Imatinib
Merve Ergül, Mustafa Ergül
Cumhuriyet Medical Journal.2018;[Epub] CrossRef
Value of pH regulators in the diagnosis, prognosis and treatment of cancer
Sara Granja, Diana Tavares-Valente, Odília Queirós, Fátima Baltazar
Seminars in Cancer Biology.2017; 43: 17. CrossRef
Triple-edged therapy targeting intracellular alkalosis and extracellular acidosis in cancer
Tomas Koltai
Seminars in Cancer Biology.2017; 43: 139. CrossRef

11,388 View
400 Download
21 Web of Science
18 Crossref

Tumor Growth Suppression and Enhanced Radioresponse by an Exogenous Epidermal Growth Factor in Mouse Xenograft Models with A431 Cells: Yu Jin Lim, Sang-Rok Jeon, Jae Moon Koh, Hong-Gyun Wu; Cancer Res Treat. 2015;47(4):921-930. Published online January 7, 2015; DOI: https://doi.org/10.4143/crt.2014.153

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to evaluate whether an exogenous epidermal growth factor (EGF) could induce anti-tumor and radiosensitizing effects in vivo.
Materials and Methods
BALB/c-nu mice that were inoculated with A431 (human squamous cell carcinoma) cells in the right hind legs were divided into five groups: I (no treatment), II (EGF for 6 days), III (EGF for 20 days), IV (radiotherapy [RT]), and V (RT plus concomitant EGF). EGF was administered intraperitoneally (5 mg/kg) once a day and the RT dose was 30 Gy in six fractions. Hematoxylin and eosin (H&E) stained sections of tumor, liver, lung, and kidney tissues were investigated. Additionally, tumors were subjected to immunohistochemistry staining with caspase-3.
Results
EGF for 6 days decreased tumor volume, but it approached the level of the control group at the end of follow-up (p=0.550). The duration of tumor shrinkage was prolonged in group V while the slope of tumor re-growth phase was steeper in group IV (p=0.034). EGF for 20 days decreased tumor volume until the end of the observation period (p < 0.001). Immunohistochemistry revealed that mice in group V showed stronger intensity than those in group IV. There were no abnormal histological findings upon H&E staining of the normal organs.
Conclusion
EGF-induced anti-tumor effect was ascertained in the xenograft mouse models with A431 cells. Concomitant use of EGF has the potential role as a radiosensitizer in the design of fractionated irradiation.

Citations

Citations to this article as recorded by

Receptor Elimination by E3 Ubiquitin Ligase Recruitment (REULR): A Targeted Protein Degradation Toolbox
Dirk H. Siepe, Lora K. Picton, K. Christopher Garcia
ACS Synthetic Biology.2023; 12(4): 1081. CrossRef
Identification of Genes Involved in EGF-induced Apoptosis Using CRISPR/Cas9 Knockout Screening: Implications for Novel Therapeutic Targets in EGFR-Overexpressing Cancers
Jae Sik Kim, Joo Ho Lee, Sang-Rok Jeon, Yongsub Kim, Seung Hyuck Jeon, Hong-Gyun Wu
Cancer Research and Treatment.2023; 55(3): 737. CrossRef
DNA damage alters EGFR signaling and reprograms cellular response via Mre-11
Yael Volman, Ruth Hefetz, Eithan Galun, Jacob Rachmilewitz
Scientific Reports.2022;[Epub] CrossRef
Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts
Jiadong Cui, Yan Zhang, Di Su, Tao Li, Yu Li
Thoracic Cancer.2018; 9(9): 1156. CrossRef
Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand
Remah Ali, Wells Brown, Stephen Connor Purdy, V. Jo Davisson, Michael K. Wendt
Cell Death & Disease.2018;[Epub] CrossRef
The paradoxical functions of EGFR during breast cancer progression
Remah Ali, Michael K Wendt
Signal Transduction and Targeted Therapy.2017;[Epub] CrossRef
Efficacy of radiotherapy for the treatment of cystic echinococcosis in naturally infected sheep
Rui Mao, Wen-Bao Zhang, Hong-Zhi Qi, Tao Jiang, Ge Wu, Peng-Fei Lu, Abudula Ainiwaer, Ge Shang, Lin Xu, Jie Hao, Xi Shou, Hai-Tao Li, Jun Li, Song-An Zhang, Yong-Xing Bao, Hao Wen
Infectious Diseases of Poverty.2017;[Epub] CrossRef
Epidermal Growth Factor Enhances Cellular Uptake of Polystyrene Nanoparticles by Clathrin-Mediated Endocytosis
Le Phuc, Akiyoshi Taniguchi
International Journal of Molecular Sciences.2017; 18(6): 1301. CrossRef

16,217 View
127 Download
9 Web of Science
8 Crossref

A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy: Hee Yeon Lee, Hoon-Kyo Kim, Kyung Hee Lee, Bong-Seog Kim, Hong Suk Song, Sung Hyun Yang, Joon Hee Kim, Yeul Hong Kim, Jong Gwang Kim, Sang-We Kim, Dong-Wan Kim, Si-Young Kim, Hee Sook Park; Cancer Res Treat. 2014;46(1):19-26. Published online January 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.1.19

Abstract PDF PubReader ePub

PURPOSE
This study was conducted to evaluate the efficacy and safety of azasetron compared to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting.
MATERIALS AND METHODS
This study was a multi-center, prospective, randomized, double-dummy, double-blind and parallel-group trial involving 12 institutions in Korea between May 2005 and December 2005. A total of 265 patients with moderately and highly emetogenic chemotherapy were included and randomly assigned to either the azasetron or ondansetron group. All patients received azasetron (10 mg intravenously) and dexamethasone (20 mg intravenously) on day 1 and dexamethasone (4 mg orally every 12 hours) on days 2-4. The azasetron group received azasetron (10 mg orally) with placebo of ondansetron (orally every 12 hours), and the ondansetron group received ondansetron (8 mg orally every 12 hours) with placebo of azasetron (orally) on days 2-6.
RESULTS
Over days 2-6, the effective ratio of complete response in the azasetron and ondansetron groups was 45% and 54.5%, respectively (95% confidence interval, -21.4 to 2.5%). Thus, the non-inferiority of azasetron compared with ondansetron in delayed chemotherapy-induced nausea and vomiting was not proven in the present study. All treatments were well tolerated and no unexpected drug-related adverse events were reported. The most common adverse events related to the treatment were constipation and hiccups, and there were no differences in the overall incidence of adverse events.
CONCLUSION
In the present study, azasetron showed inferiority in the control of delayed chemotherapy-induced nausea and vomiting compared with ondansetron whereas safety profiles were similar between the two groups.

Citations

Citations to this article as recorded by

Influence of ABCB1 genetic polymorphisms on the antiemetic response to ondansetron-based medication for cisplatin-based chemotherapy in South Indian cancer patients in a tertiary care hospital
Ayyar Porkodi, Deepak Gopal Shewade, Goud Alladi Charanraj
Current Issues in Pharmacy and Medical Sciences.2023; 36(3): 129. CrossRef
Hiccups in Cancer Patients Receiving Chemotherapy: A Cross-Sectional Study
Mevlüde Ergen, Fatma Arikan, Rüya Fırat Çetin
Journal of Pain and Symptom Management.2021; 62(3): e85. CrossRef
A Fast and Validated HPLC Method for the Simultaneous Analysis of Five 5-HT3 Receptor Antagonists via the Quantitative Analysis of Multicomponents by a Single Marker
Fuchao Chen, Baoxia Fang, Peng Li, Sicen Wang, Amr M. Mahmoud
International Journal of Analytical Chemistry.2021; 2021: 1. CrossRef
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis
Vanessa Piechotta, Anne Adams, Madhuri Haque, Benjamin Scheckel, Nina Kreuzberger, Ina Monsef, Karin Jordan, Kathrin Kuhr, Nicole Skoetz
Cochrane Database of Systematic Reviews.2021;[Epub] CrossRef
Effectiveness of Steroid Rotation in a Japanese Patient with Hiccups Caused by Dexamethasone: a Case Report
Hiroki Hosokawa, Hideaki Shimoda, Takayuki Ishii
YAKUGAKU ZASSHI.2019; 139(4): 647. CrossRef
Stability of azasetron-dexamethasone mixture for chemotherapy-induced nausea and vomiting administration
Bao-Xia Fang, Fu-Chao Chen, Dan Zhu, Jun Guo, Lin-Hai Wang
Oncotarget.2017; 8(63): 106249. CrossRef
Gender Differences in Hiccup Patients: Analysis of Published Case Reports and Case-Control Studies
Gyeong-Won Lee, Rock Bum Kim, Se Il Go, Hyun Seop Cho, Seung Jun Lee, David Hui, Eduardo Bruera, Jung Hun Kang
Journal of Pain and Symptom Management.2016; 51(2): 278. CrossRef
Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting
Bishal Gyawali, Bishesh Sharma Poudyal, Mahesh Iddawela
Journal of Global Oncology.2016; 2(3): 145. CrossRef
Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review
K. Jordan, F. Jahn, M. Aapro
Annals of Oncology.2015; 26(6): 1081. CrossRef

12,154 View
70 Download
8 Web of Science
9 Crossref

First
Prev
Page of 1
Next
Last

Search